5 research outputs found
Detection techniques of circular RNAs as new biomarkers in systemic lupus erythematosus
Systemic lupus erythematosus (SLE) is severe, chronic autoimmune disease affecting mainly young active individuals, leading to disability and premature death. Recent studies have reported long non-coding RNAs (lncRNAs) to participate in the pathogenesis of the disease. Among lncRNAs, the circular RNAs (circRNAs) gain growing scientific attention due to their stability in body fluids. This makes them suitable for new non-biomarkers for evaluation of SLE activity and promising therapeutic targets. Methods for detecting of circRNAs are evolving rapidly. The aim of this review is to present these techniques and their advantages and disadvantages
The Role Of The Complement System In Rheumatic Diseases
Π‘ΠΈΡΡΠ΅ΠΌΠ°ΡΠ° Π½Π° ΠΊΠΎΠΌΠΏΠ»Π΅ΠΌΠ΅Π½ΡΠ° ΠΈΠ³ΡΠ°Π΅ ΠΊΠ»ΡΡΠΎΠ²Π° ΡΠΎΠ»Ρ Π² ΠΈΠΌΡΠ½ΠΈΡΠ΅ΡΠ° Π½Π° ΠΎΡΠ³Π°Π½ΠΈΠ·ΠΌΠ° - ΠΎΡ Π΅Π΄Π½Π° ΡΡΡΠ°Π½Π° ΠΏΡΡΠΊΠΎ ΠΏΡΠ΅Π΄ΠΏΠ°Π·Π²Π° ΠΎΡ ΠΏΠ°ΡΠΎΠ³Π΅Π½ΠΈ, ΠΏΠΎΠ΄ΠΏΠΎΠΌΠ°Π³Π° Ρ
ΡΠΌΠΎΡΠ°Π»Π½ΠΈΡ ΠΈΠΌΡΠ½Π΅Π½ ΠΎΡΠ³ΠΎΠ²ΠΎΡ, ΠΎΡΠΈΡΡΠ²Π° Π½Π°ΡΡΡΠΏΠ°Π½ΠΈΡΠ΅ ΠΈΠΌΡΠ½Π½ΠΈ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠΈ, Π°ΠΏΠΎΠΏΡΠΎΡΠΈΡΠ½ΠΈ ΠΊΠ»Π΅ΡΠΊΠΈ ΠΈ Π΄Ρ. ΠΡ Π΄ΡΡΠ³Π° ΡΡΡΠ°Π½Π° Π΄ΠΈΡΡΠ΅Π³ΡΠ»Π°ΡΠΈΡΡΠ° ΠΈ ΡΠ²ΡΡΡ
Π°ΠΊΡΠΈΠ²ΠΈΡΠ°Π½Π΅ΡΠΎ Π½Π° ΠΊΠΎΠΌΠΏΠ»Π΅ΠΌΠ΅Π½ΡΠ°, ΠΎΡΠΎΠ±Π΅Π½ΠΎ Π½Π°ΡΠΎΡΠ΅Π½ΠΎ ΡΡΠ΅ΡΡ ΡΠΎΠ±ΡΡΠ²Π΅Π½ΠΈ ΡΡΡΡΠΊΡΡΡΠΈ ΠΈΠΌΠ° Π²Π°ΠΆΠ½ΠΈ ΠΏΠ°ΡΠΎΠ³Π΅Π½Π΅ΡΠΈΡΠ½ΠΈ ΠΏΠΎΡΠ»Π΅Π΄ΠΈΡΠΈ ΠΏΡΠΈ ΡΠ΅Π΄ΠΈΡΠ° Π°Π²ΡΠΎΠΈΠΌΡΠ½Π½ΠΈ Π·Π°Π±ΠΎΠ»ΡΠ²Π°Π½ΠΈΡ. Π£ΡΠ°ΡΡΠΈΠ΅ΡΠΎ Π½Π° ΡΠΈΡΡΠ΅ΠΌΠ°ΡΠ° Π½Π° ΠΊΠΎΠΌΠΏΠ»Π΅ΠΌΠ΅Π½ΡΠ° Π² ΠΏΠ°ΡΠΎΠ³Π΅Π½Π΅Π·Π°ΡΠ° Π½Π° ΡΠ΅Π²ΠΌΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ½ΠΈ Π·Π°Π±ΠΎΠ»ΡΠ²Π°Π½ΠΈΡ Π΅ Π΄ΠΎΠΊΠ°Π·Π°Π½ΠΎ, Π½ΠΎ ΠΈΠ·ΡΡΠ½ΡΠ²Π°Π½Π΅ΡΠΎ Π½Π° ΠΈΠ½ΡΠΈΠΌΠ½ΠΈΡΠ΅ ΠΌΠ΅Ρ
Π°Π½ΠΈΠ·ΠΌΠΈ, ΠΊΠΎΠΈΡΠΎ Ρ ΡΠ²ΡΡΠ·Π²Π°Ρ Ρ Π½Π°ΠΌΠ΅ΡΠ΅Π½ΠΈΡΠ΅ ΠΌΠ½ΠΎΠ³ΠΎ Π΄ΡΡΠ³ΠΈ ΠΈΠ½ΡΠ»Π°ΠΌΠ°ΡΠΎΡΠ½ΠΈ ΠΏΡΡΠΈΡΠ°, Π²ΡΠ΅ ΠΎΡΠ΅ Π΅ ΠΏΡΠ΅Π΄ΠΈΠ·Π²ΠΈΠΊΠ°ΡΠ΅Π»ΡΡΠ²ΠΎ. Π¦Π΅Π»ΡΠ° Π½Π° Π½Π°ΡΡΠΎΡΡΠΈΡ ΠΎΠ±Π·ΠΎΡ Π΅ ΠΎΠ±ΠΎΠ±ΡΠ΅Π½ΠΈΠ΅ Π½Π° ΠΏΠΎΡΠ»Π΅Π΄Π½ΠΈΡΠ΅ Π½Π°ΡΡΠ½ΠΈ Π΄Π°Π½Π½ΠΈ Π·Π° ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ½ΠΎΡΠΎ Π·Π½Π°ΡΠ΅Π½ΠΈΠ΅ Π½Π° ΡΠΈΡΡΠ΅ΠΌΠ°ΡΠ° Π½Π° ΠΊΠΎΠΌΠΏΠ»Π΅ΠΌΠ΅Π½ΡΠ° Π·Π° ΡΠ°Π·Π²ΠΈΡΠΈΠ΅ΡΠΎ ΠΈ ΠΏΡΠΎΠ³ΡΠ΅ΡΠΈΡΡΠ° Π½Π° Π½ΡΠΊΠΎΠΈ ΡΠ΅Π²ΠΌΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ½ΠΈ Π·Π°Π±ΠΎΠ»ΡΠ²Π°Π½ΠΈΡ, ΡΡΠ²ΡΡΠ΄Π΅Π½ΠΈΡΠ΅ Π΄ΠΎ ΠΌΠΎΠΌΠ΅Π½ΡΠ° ΡΠ΅ΡΠ°ΠΏΠ΅Π²ΡΠΈΡΠ½ΠΈ ΡΡΡΠ°ΡΠ΅Π³ΠΈΠΈ, Π²ΠΊΠ»ΡΡΠ²Π°ΡΠΈ ΠΈΠ½Ρ
ΠΈΠ±ΠΈΡΠ°Π½Π΅ Π½Π° ΠΊΠΎΠΌΠΏΠ»Π΅ΠΌΠ΅Π½ΡΠ½ΠΈ ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½ΡΠΈ ΠΈ Π΅Π²Π΅Π½ΡΡΠ°Π»Π½ΠΈΡΠ΅ Π±ΡΠ΄Π΅ΡΠΈ Π½Π°ΡΠΎΠΊΠΈ Π·Π° ΡΠ°Π·Π²ΠΈΡΠΈΠ΅ Π½Π° ΡΠΎΠ·ΠΈ ΠΈΠ½ΡΠ΅ΡΠ΅ΡΠ΅Π½ ΠΈΠ·ΡΠ»Π΅Π΄ΠΎΠ²Π°ΡΠ΅Π»ΡΠΊΠΈ ΠΏΡΠΎΠ±Π»Π΅ΠΌ.The complement system is a key player in immunity - on one hand it defends the organisms from pathogenes, helps the humoral response, clears the immune complexes, apoptotic cells, etc. On the other hand, dysregulation and overactivation of the complement, mostly targeted against own structures has important pathogenetic role in a number of autoimmune diseases. There is a growing body of evidence for the participation of the complement system in the pathogenesis of some rheumatic diseases, but unraveling the intimate mechanisms connecting it with the other numerous inflammatory pathways, is still a major challenge. In this review we try to summarize the scientific data for the complex role of the complement system in the development and progression of some rheumatic diseases; the established therapeutic strategies targeting complement components and the future perspectives for this field of research
The challenge to manage a patient with advanced heart failure and necrotizing vasculitis - a clinical case
ΠΠ°ΡΠΈΠ΅Π½ΡΠΈΡΠ΅ Ρ Π½Π°ΠΏΡΠ΅Π΄Π½Π°Π»Π° ΡΡΡΠ΄Π΅ΡΠ½Π° Π½Π΅Π΄ΠΎΡΡΠ°ΡΡΡΠ½ΠΎΡΡ ΠΌΠ½ΠΎΠ³ΠΎ ΡΠ΅ΡΡΠΎ ΠΈΠΌΠ°Ρ ΠΈ ΠΏΡΠΈΠ΄ΡΡΠΆΠ°Π²Π°ΡΠΈ Π·Π°Π±ΠΎΠ»ΡΠ²Π°Π½ΠΈΡ, ΠΊΠΎΠΈΡΠΎ ΠΏΠΎΠ²Π»ΠΈΡΠ²Π°Ρ ΠΈ ΠΎΠ³ΡΠ°Π½ΠΈΡΠ°Π²Π°Ρ ΠΈΠ·Π±ΠΎΡΠ° Π½Π° Π»Π΅ΡΠ΅Π½ΠΈΠ΅ ΠΊΠ°ΠΊΡΠΎ Π·Π° ΡΡΡΠ΄Π΅ΡΠ½Π°ΡΠ° Π½Π΅Π΄ΠΎΡΡΠ°ΡΡΡΠ½ΠΎΡΡ, ΡΠ°ΠΊΠ° ΠΈ Π·Π° ΠΏΡΠΈΠ΄ΡΡΠΆΠ°Π²Π°ΡΠΎΡΠΎ Π·Π°Π±ΠΎΠ»ΡΠ²Π°Π½Π΅. ΠΡΠ΅Π΄ΡΡΠ²ΡΠΌΠ΅ ΠΌΡΠΆ, Π½Π° 64Π³ΠΎΠ΄ΠΈΠ½ΠΈ, Ρ ΠΌΠ΅Ρ
Π°Π½ΠΈΡΠ½Π° ΠΊΠ»Π°ΠΏΠ½Π° ΠΏΡΠΎΡΠ΅Π·Π° Π½Π° Π°ΠΎΡΡΠ½ΠΎ ΠΌΡΡΡΠΎ, Ρ Π²ΠΈΡΠΎΠΊΠΎΡΡΠ΅ΠΏΠ΅Π½Π½Π° ΡΡΠΈΠΊΡΡΠΏΠΈΠ΄Π°Π»Π½Π° ΡΠ΅Π³ΡΡΠ³ΠΈΡΠ°ΡΠΈΡ ΠΈ Π²ΠΈΡΠΎΠΊΠΎΡΡΠ΅ΠΏΠ΅Π½Π½Π° ΠΏΡΠ»ΠΌΠΎΠ½Π°Π»Π½Π° Ρ
ΠΈΠΏΠ΅ΡΡΠΎΠ½ΠΈΡ, Ρ ΡΠΎΡΠ°Π»Π½Π° ΡΡΡΠ΄Π΅ΡΠ½Π° Π½Π΅Π΄ΠΎΡΡΠ°ΡΡΡΠ½ΠΎΡΡ, Π·Π°Ρ
Π°ΡΠ΅Π½ Π΄ΠΈΠ°Π±Π΅Ρ, ΠΏΠ΅ΡΠΈΡΠ΅ΡΠ½Π° Π°ΡΡΠ΅ΡΠΈΠ°Π»Π½Π° Π±ΠΎΠ»Π΅ΡΡ ΠΈ Π½Π΅ΠΊΡΠΎΡΠΈΠ·ΠΈΡΠ°Ρ Π²Π°ΡΠΊΡΠ»ΠΈΡ. ΠΠ΅ΡΠ΅Π½ΠΈΠ΅ΡΠΎ, ΠΊΠΎΠ΅ΡΠΎ Π±Π΅ ΠΏΡΠ΅Π΄ΠΏΡΠΈΠ΅ΡΠΎ Π΅ Π½Π°ΠΏΡΠ»Π½ΠΎ ΡΡΠΎΠ±ΡΠ°Π·Π΅Π½ΠΎ Ρ ΠΏΡΠ΅ΠΏΠΎΡΡΠΊΠΈΡΠ΅ Π·Π° Π»Π΅ΡΠ΅Π½ΠΈΠ΅ Π½Π° ΡΡΡΠ΄Π΅ΡΠ½Π° Π½Π΅Π΄ΠΎΡΡΠ°ΡΡΡΠ½ΠΎΡΡ Π½Π° ΠΠ²ΡΠΎΠΏΠ΅ΠΉΡΠΊΠΎΡΠΎ Π΄ΡΡΠΆΠ΅ΡΡΠ²ΠΎ ΠΏΠΎ ΠΠ°ΡΠ΄ΠΈΠΎΠ»ΠΎΠ³ΠΈΡ ΠΎΡ 2016 Π³ΠΎΠ΄., ΠΊΠ°ΠΊΡΠΎ ΠΈ ΡΡΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΠΈΡΠ΅ ΠΏΡΠ΅ΠΏΠΎΡΡΠΊΠΈ Π·Π° Π»Π΅ΡΠ΅Π½ΠΈΠ΅ Π½Π° Π·Π°Ρ
Π°ΡΠ΅Π½ Π΄ΠΈΠ°Π±Π΅Ρ ΠΈ Π²Π°ΡΠΊΡΠ»ΠΈΡΠΈ.Patients with advanced heart failure are patients with a lot of comorbidities that have important influence on the options of treatment - both for heart failure and the concomitant diseases. Here we present a 64-year-old man with mechanical aortic valve prosthesis, severe tricuspid regurgitation, severe pulmonary hypertension and total heart failure, diabetes mellitus type 2, peripheral artery disease and necrotizing vasculitis. The management of heart failure is according to the guidelines for the treatment of patients with heart failure of the European Society of Cardiology 2016; the treatment of the diabetes mellitus and the necrotizing vasculitis is also in accordance with the latest recommendations
Risk Of Development Of Solid Tumors In Patients With Systemic Lupus Erythematosus
Π‘ΠΈΡΡΠ΅ΠΌΠ½ΠΈΡΡ Π»ΡΠΏΡΡ Π΅ΡΠΈΡΠ΅ΠΌΠ°ΡΠΎΠ·ΡΡ (Π‘ΠΠ) Π΅ Π°Π²ΡΠΎΠΈΠΌΡΠ½Π½ΠΎ Π·Π°Π±ΠΎΠ»ΡΠ²Π°Π½Π΅, Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΠ·ΠΈΡΠ°ΡΠΎ ΡΠ΅ Ρ ΠΏΡΠΎΠ΄ΡΡΠΈΡΠ°Π½Π΅ Π½Π° ΡΠ°Π·Π»ΠΈΡΠ½ΠΈ Π°Π²ΡΠΎΠ°Π½ΡΠΈΡΠ΅Π»Π°, Π°ΠΊΡΠΈΠ²ΠΈΡΠ°Π½Π΅ Π½Π° ΠΊΠΎΠΌΠΏΠ»Π΅ΠΌΠ΅Π½ΡΠ° ΠΈ ΠΎΡΠ»Π°Π³Π°Π½Π΅ Π½Π° ΠΈΠΌΡΠ½Π½ΠΈ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠΈ. ΠΡΡΠ·ΠΊΠ°ΡΠ° ΠΌΠ΅ΠΆΠ΄Ρ Π‘ΠΠ ΠΈ ΡΠ°ΠΊΠ° ΠΎΡΠ΄Π°Π²Π½Π° Π΅ ΡΡΡΠ°Π½ΠΎΠ²Π΅Π½Π°. ΠΡΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΈ ΡΡΡ Π‘ΠΠ ΡΠ΅ΡΡΠΎΡΠ°ΡΠ° ΠΈ ΡΠΈΡΠΊΡΡ ΠΎΡ Π·Π»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½ΠΎ Π·Π°Π±ΠΎΠ»ΡΠ²Π°Π½Π΅ ΡΠ΅ ΡΠ²Π΅Π»ΠΈΡΠ°Π²Π° Π·Π° Π±Π΅Π»ΠΎΠ΄ΡΠΎΠ±Π΅Π½ ΠΊΠ°ΡΡΠΈΠ½ΠΎΠΌ, ΡΠ°ΠΊ Π½Π° ΡΠΈΠΉΠΊΠ°ΡΠ° Π½Π° ΠΌΠ°ΡΠΊΠ°ΡΠ°, Ρ
Π΅ΠΏΠ°ΡΠΎΡΠ΅Π»ΡΠ»Π°ΡΠ΅Π½ ΠΊΠ°ΡΡΠΈΠ½ΠΎΠΌ ΠΈ Π΄Ρ. Π ΡΡΡΠΎΡΠΎ Π²ΡΠ΅ΠΌΠ΅ ΡΠ΅ΡΡΠΎΡΠ°ΡΠ° Π½Π° ΠΊΠ°ΡΡΠΈΠ½ΠΎΠΌ Π½Π° Π³ΡΡΠ΄Π°ΡΠ°, Π½Π° ΠΏΡΠΎΡΡΠ°ΡΠ½Π°ΡΠ° ΠΆΠ»Π΅Π·Π° ΠΈ ΡΠΉΡΠ½ΠΈΡΠΈΡΠ΅ Π΅ Π½ΠΈΡΠΊΠ° Π² ΡΠ΅Π΄ΠΈΡΠ° ΠΏΡΠΎΡΡΠ²Π°Π½ΠΈΡ Π½Π° Π‘ΠΠ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΈ.ΠΠ·Π²Π΅ΡΡΠ½ΠΈ ΡΠ° ΡΠ΅Π΄ΠΈΡΠ° ΡΠ°ΠΊΡΠΎΡΠΈ, ΠΊΠΎΠΈΡΠΎ ΠΌΠΎΠ³Π°Ρ Π΄Π° Π΄ΠΎΠΏΡΠΈΠ½Π΅ΡΠ°Ρ Π·Π° ΡΠ°Π·Π²ΠΈΡΠΈΠ΅ΡΠΎ Π½Π° Π·Π»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½ΠΈ Π·Π°Π±ΠΎΠ»ΡΠ²Π°Π½ΠΈΡ ΠΏΡΠΈ Π‘ΠΠ. Π ΡΠΎΠ·ΠΈ ΠΏΡΠ΅Π³Π»Π΅Π΄ Π½ΠΈΠ΅ ΠΏΡΠ΅Π΄ΡΡΠ°Π²ΡΠΌΠ΅ Π½ΡΠΊΠΎΠΈ ΠΏΠΎ-ΡΠ΅ΡΡΠΎ ΡΡΠ΅ΡΠ°Π½ΠΈ ΡΠΎΠ»ΠΈΠ΄Π½ΠΈ ΡΡΠΌΠΎΡΠΈ ΠΈ ΡΡΡ
Π½Π°ΡΠ° ΡΠ΅ΡΡΠΎΡΠ° ΠΏΡΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΈ ΡΡΡ Π‘ΠΠ, ΠΊΠ°ΠΊΡΠΎ ΠΈ ΡΠ°ΠΊΡΠΎΡΠΈΡΠ΅, ΠΊΠΎΠΈΡΠΎ Π²Π»ΠΈΡΡΡ Π½Π° ΡΡΠΌΠΎΡΠΎΠ³Π΅Π½Π΅Π·Π°ΡΠ° Π² ΡΡΠ»ΠΎΠ²ΠΈΡΡΠ° Π½Π° Π°Π²ΡΠΎΠΈΠΌΡΠ½Π½ΠΎ Π·Π°Π±ΠΎΠ»ΡΠ²Π°Π½Π΅.Systemic lupus erythematosus (SLE) is an autoimmune disease, characterized by production of different autoantibodies, complement activation, and immune complex deposition. An association between SLE and cancer has long been known. In patients with SLE, the incidence and risk of overall malignancy is increased for lung cancer, cervical cancer, liver cancer, and etc. Conversely, the incidences of prostate, breast and ovarial cancers are decreased in a number of studies of SLE patients.There are many factors, which can contribute to the development of malignancies in SLE. In this review we present some more common solid tumors and their incidence in SLE patients as well as the factors that affect tumorigenesis in conditions of autoimmune disease
Frequency and Clinic-Immunological Correlations of Some C1q-Snps in Patients with Rheumatoid Arthritis and Systemic Lupus Erythematosus // Π§Π΅ΡΡΠΎΡΠ° ΠΈ ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-ΠΈΠΌΡΠ½ΠΎΠ»ΠΎΠ³ΠΈΡΠ½ΠΈ ΠΊΠΎΡΠ΅Π»Π°ΡΠΈΠΈ Π½Π° Π½ΡΠΊΠΎΠΈ C1q-SNPs ΠΏΡΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΈ Ρ ΡΠ΅Π²ΠΌΠ°ΡΠΎΠΈΠ΄Π΅Π½ Π°ΡΡΡΠΈΡ ΠΈ ΡΠΈΡΡΠ΅ΠΌΠ΅Π½ Π»ΡΠΏΡΡ Π΅ΡΠΈΡΠ΅ΠΌΠ°ΡΠΎΠ΄Π΅Ρ
The study aims to assess Bulgarian RA and SLE patients and healthy controls for 5 SNPs (rs665691, rs682658, rs172378, rs294179 and rs292001) in the C1q gene cluster to analyze their associations with C1q levels and some of the disease specific clinical and immunological aspects.
This cross-sectional case-control cohort study included 111 subjects (58 RA and 53 SLE) and 67 healthy controls. Information about both diseases' clinical, laboratory, immunological, and therapeutic aspects were collected. SNP genotyping was performed on extracted DNA using a TaqMan allelic discrimination assay, and C1q levels were quantified using ELISA.
Associations were found between rs172378 and RA and SLE, early SLE onset, LN and anti-dsDNA positivity; between rs292001 and RA: between rs665691 (and to a lesser extent rs294179) and higher C1q levels and ACPA positivity.
C1q levels were found to be lower (still normal) in RA patients compared to healthy controls and even lower in SLE patients and the LN subgroup, where values below the reference range were noted.
Haplotype analysis was performed, demonstrating almost complete LD between all the five SNPs in the healthy control group. Due to the disease associations of rs172378 in RA and even more in SLE patients, it showed no LD with the other SNPs.
Despite some limitations, the study outlines the multifaceted and promising etiopathogenetic role of C1q gene polymorphisms in RA and SLE, which have to be considered in their complex understanding.Π¦Π΅Π»ΡΠ° Π½Π° ΠΏΡΠΎΡΡΠ²Π°Π½Π΅ΡΠΎ Π΅ ΠΈΠ·ΡΠ»Π΅Π΄Π²Π°Π½Π΅ Π½Π° Π±ΡΠ»Π³Π°ΡΡΠΊΠ° ΠΊΠΎΡ
ΠΎΡΡΠ° Π±ΠΎΠ»Π½ΠΈ ΠΎΡ Π Π ΠΈ Π‘ΠΠ ΠΈ ΠΊΠΎΠ½ΡΡΠΎΠ»Π½Π° Π³ΡΡΠΏΠ° Π·Π΄ΡΠ°Π²ΠΈ ΠΈΠ½Π΄ΠΈΠ²ΠΈΠ΄ΠΈ Π·Π° Π½Π°Π»ΠΈΡΠΈΠ΅ Π½Π° 5 SNPs (rs665691, rs682658, rs172378, rs294179 ΠΈ rs292001) Π² Π³Π΅Π½ΠΈΡΠ΅ Π·Π° C1q, Π°Π½Π°Π»ΠΈΠ· Π½Π° Π°ΡΠΎΡΠΈΠ°ΡΠΈΠΈΡΠ΅ ΠΈΠΌ Ρ ΠΏΠ»Π°Π·ΠΌΠ΅Π½ΠΈΡΠ΅ Π½ΠΈΠ²Π° Π½Π° C1q ΠΈ Ρ Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠ½ΠΈΡΠ΅ Π·Π° Π΄Π²Π΅ΡΠ΅ Π·Π°Π±ΠΎΠ»ΡΠ²Π°Π½ΠΈΡ ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-ΠΈΠΌΡΠ½ΠΎΠ»ΠΎΠ³ΠΈΡΠ½ΠΈ ΠΏΡΠΎΡΠ²ΠΈ.
111 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ° (58 Π Π ΠΈ 53 Π‘ΠΠ) ΠΈ 67 Π·Π΄ΡΠ°Π²ΠΈ ΠΈΠ½Π΄ΠΈΠ²ΠΈΠ΄ΠΈ ΡΠ° Π²ΠΊΠ»ΡΡΠ΅Π½ΠΈ Π² ΡΡΠ΅Π·ΠΎΠ²ΠΎ ΠΈΠ·ΡΠ»Π΅Π΄Π²Π°Π½Π΅ ΠΎΡ ΡΠΈΠΏΠ° ΡΠ»ΡΡΠ°ΠΉ/ΠΊΠΎΠ½ΡΡΠΎΠ»Π°. Π‘ΡΠ±ΡΠ°Π½Π° Π΅ ΠΊΠ»ΠΈΠ½ΠΈΡΠ½Π°, Π»Π°Π±ΠΎΡΠ°ΡΠΎΡΠ½Π°, ΠΈΠΌΡΠ½ΠΎΠ»ΠΎΠ³ΠΈΡΠ½Π° ΠΈ ΡΠ΅ΡΠ°ΠΏΠ΅Π²ΡΠΈΡΠ½Π° ΠΈΠ½ΡΠΎΡΠΌΠ°ΡΠΈΡ ΠΈ Π²ΡΠΈΡΠΊΠΈ ΡΡΠ°ΡΡΠ½ΠΈΡΠΈ ΡΠ° Π³Π΅Π½ΠΎΡΠΈΠΏΠΈΠ·ΠΈΡΠ°Π½ΠΈ Π·Π° ΠΏΠ΅ΡΡΠ΅ SNPs ΡΡΠ΅Π· TaqMan Π°Π½Π°Π»ΠΈΠ·. ΠΠΈΠ²Π°ΡΠ° Π½Π° C1q ΡΠ° ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈ Ρ ELISA.
Π£ΡΡΠ°Π½ΠΎΠ²Π΅Π½ΠΈ ΡΠ° Π°ΡΠΎΡΠΈΠ°ΡΠΈΠΈ ΠΌΠ΅ΠΆΠ΄Ρ rs172378 ΠΈ Π Π ΠΈ Π‘ΠΠ, ΡΠ°Π½Π½ΠΎ Π½Π°ΡΠ°Π»ΠΎ Π½Π° Π‘ΠΠ, ΠΠ ΠΈ Π½ΠΎΡΠΈΡΠ΅Π»ΡΡΠ²ΠΎ Π½Π° anti-dsDNA; ΠΌΠ΅ΠΆΠ΄Ρ rs292001 ΠΈ Π Π; ΠΌΠ΅ΠΆΠ΄Ρ rs665691 (ΠΈ Π² ΠΏΠΎ-ΠΌΠ°Π»ΠΊΠ° ΡΡΠ΅ΠΏΠ΅Π½ rs294179) ΠΈ ΠΏΠΎΠ²ΠΈΡΠ΅Π½ΠΈ Π½ΠΈΠ²Π° Π½Π° C1q ΠΈ Π½ΠΎΡΠΈΡΠ΅Π»ΡΡΠ²ΠΎ Π½Π° ΠΠ‘Π Π.
Π£ΡΡΠ°Π½ΠΎΠ²Π΅Π½ΠΈ ΡΠ° ΠΏΠΎ-Π½ΠΈΡΠΊΠΈ Π½ΠΈΠ²Π° (Π² ΡΠ°ΠΌΠΊΠΈΡΠ΅ Π½Π° Π½ΠΎΡΠΌΠ°ΡΠ°) Π½Π° C1q ΠΏΡΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΈΡΠ΅ Ρ Π Π Π² ΡΡΠ°Π²Π½Π΅Π½ΠΈΠ΅ ΡΡΡ Π·Π΄ΡΠ°Π²ΠΈ ΠΈΠ½Π΄ΠΈΠ²ΠΈΠ΄ΠΈ ΠΈ ΠΎΡΠ΅ ΠΏΠΎ-Π½ΠΈΡΠΊΠΈ ΠΏΡΠΈ Π±ΠΎΠ»Π½ΠΈΡΠ΅ ΠΎΡ Π‘ΠΠ ΠΈ Π² ΠΏΠΎΠ΄Π³ΡΡΠΏΠ°ΡΠ° Π½Π° ΠΠ, ΠΊΡΠ΄Π΅ΡΠΎ Π½ΡΠΊΠΎΠΈ ΠΎΡ ΡΡΠΎΠΉΠ½ΠΎΡΡΠΈΡΠ΅ ΡΠ° ΠΏΠΎΠ΄ Π΄ΠΎΠ»Π½Π°ΡΠ° ΡΠ΅ΡΠ΅ΡΠ΅Π½ΡΠ½Π° Π³ΡΠ°Π½ΠΈΡΠ°.
ΠΡΡΡΠ΅ΡΡΠ²Π΅Π½ Π΅ Ρ
Π°ΠΏΠ»ΠΎΡΠΈΠΏΠ΅Π½ Π°Π½Π°Π»ΠΈΠ·, ΠΊΠΎΠΉΡΠΎ Π΄Π΅ΠΌΠΎΠ½ΡΡΡΠΈΡΠ° ΠΏΠΎΡΡΠΈ ΠΏΡΠ»Π½ΠΎ LD ΠΌΠ΅ΠΆΠ΄Ρ ΠΏΠ΅ΡΡΠ΅ SNPs Π² ΠΊΠΎΠ½ΡΡΠΎΠ»Π½Π°ΡΠ° Π³ΡΡΠΏΠ° Π·Π΄ΡΠ°Π²ΠΈ. ΠΠ΅ΡΠΎΡΡΠ½ΠΎ Π·Π°ΡΠ°Π΄ΠΈ Π±ΠΎΠ»Π΅ΡΡΠ½ΠΈΡΠ΅ Π°ΡΠΎΡΠΈΠ°ΡΠΈΠΈ Π½Π° rs172378 Ρ Π Π ΠΈ ΠΎΡΠ΅ ΠΏΠΎΠ²Π΅ΡΠ΅ ΡΡΡ Π‘ΠΠ, ΠΏΡΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΈΡΠ΅ ΡΠΎΠΉ Π½Π΅ Π΅ Π² LD Ρ ΠΎΡΡΠ°Π½Π°Π»ΠΈΡΠ΅ ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΠΈΠ·ΠΌΠΈ.
ΠΡΠΏΡΠ΅ΠΊΠΈ Π½ΡΠΊΠΎΠΈ ΠΎΠ³ΡΠ°Π½ΠΈΡΠ΅Π½ΠΈΡ, ΠΏΡΠΎΡΡΠ²Π°Π½Π΅ΡΠΎ ΠΎΡΠ΅ΡΡΠ°Π²Π° ΠΌΠ½ΠΎΠ³ΠΎΠ»ΠΈΠΊΠ° ΠΈ ΠΎΠ±Π΅ΡΠ°Π²Π°ΡΠ° Π΅ΡΠΈΠΎΠΏΠ°ΡΠΎΠ³Π΅Π½Π΅ΡΠΈΡΠ½Π° ΡΠΎΠ»Ρ Π½Π° ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΠΈΠ·ΠΌΠΈΡΠ΅ Π² Π³Π΅Π½Π° Π·Π° C1q ΠΏΡΠΈ Π Π ΠΈ Π‘ΠΠ, ΠΊΠΎΡΡΠΎ ΡΠ»Π΅Π΄Π²Π° Π΄Π° ΡΠ΅ ΠΈΠΌΠ° ΠΏΡΠ΅Π΄Π²ΠΈΠ΄ Π·Π° ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ½ΠΎΡΠΎ ΠΈΠΌ ΡΠ°Π·Π±ΠΈΡΠ°Π½Π΅